Patents by Inventor David J. Bearss

David J. Bearss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11529350
    Abstract: Provided herein is a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein values for the variables (e.g., X1, X2, R2, R3, R4, R5, R6, R7, R8, m, n) are as described herein. Compounds of Formula I, pharmaceutically acceptable salts thereof, pharmaceutical compositions of either of the foregoing, and combinations of any of the foregoing can be used to treat tyrosine kinase non-receptor 1 (TNK1)-mediated diseases, disorders and conditions.
    Type: Grant
    Filed: July 2, 2020
    Date of Patent: December 20, 2022
    Assignee: Sumitomo Pharma Oncology, Inc.
    Inventors: Adam Siddiqui-Jain, Jeyaprakashnarayanan Seenisamy, Steven L. Warner, Clifford J. Whatcott, David J. Bearss
  • Patent number: 11497756
    Abstract: Methods for treating BCL-2 inhibitor-resistant cancer in subjects using an MCL-1 inhibitor as well as compositions associated with the same are disclosed.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: November 15, 2022
    Assignee: Sumitomo Pharma Oncology, Inc.
    Inventors: David J. Bearss, Adam Siddiqui-Jain, Clifford J. Whatcott, Steven L. Warner
  • Publication number: 20220339172
    Abstract: Methods of treating castration-resistant and castration-sensitive prostate cancer using a compound having the following structure (I): or a pharmaceutically acceptable salt or zwitterionic form thereof, are provided.
    Type: Application
    Filed: December 10, 2021
    Publication date: October 27, 2022
    Inventors: Steven L. Warner, David J. Bearss, Stephen Patrick Anthony, Michael Vincent McCullar
  • Publication number: 20220305037
    Abstract: Provided herein are methods of treating a hematologic cancer in a subject in need thereof, comprising administering to the subject an effective amount of alvocidib, or prodrug thereof, or a pharmaceutically acceptable salt of the foregoing. The subject is in complete remission from the hematologic cancer and measurable residual disease (MRD)-positive following administration of a prior therapy that includes venetoclax, or a pharmaceutically acceptable salt thereof, and does not include alvocidib, or a prodrug thereof, or a pharmaceutically acceptable salt of the foregoing. Other methods are also provided in accordance with other aspects of the invention.
    Type: Application
    Filed: July 8, 2020
    Publication date: September 29, 2022
    Inventors: David J. Bearss, Stephen Patrick Anthony
  • Publication number: 20220257581
    Abstract: Provided herein are methods of treating a hematologic cancer in a subject in need thereof, comprising administering to the subject an effective amount of alvocidib, or prodrug thereof, or a pharmaceutically acceptable salt of the foregoing. The subject is in complete remission from the hematologic cancer and measurable residual disease (MRD)-positive following administration of a prior therapy that does not include alvocidib, or a prodrug thereof, or a pharmaceutically acceptable salt of the foregoing, and is MRD-negative following administration of alvocidib, or a prodrug thereof, or a pharmaceutically acceptable salt of the foregoing. Other methods are also provided in accordance with other aspects of the invention.
    Type: Application
    Filed: July 8, 2020
    Publication date: August 18, 2022
    Inventors: David J. Bearss, Stephen Patrick Anthony, Michael Vincent McCullar
  • Patent number: 11400091
    Abstract: Tartrate salts of the compound of structure (I), crystalline forms thereof, and therapeutic applications thereof for treating solid tumors (e.g., advanced solid tumor) or hematopoietic cancers. Also provided herein are methods for synthesizing the tartrate salts and the crystalline forms thereof.
    Type: Grant
    Filed: November 9, 2020
    Date of Patent: August 2, 2022
    Assignee: Sumitomo Pharma Oncology, Inc.
    Inventors: Adam Siddiqui-Jain, Steven L. Warner, Paul Flynn, David J. Bearss, Jason Marc Foulks, Nozomi Tomimatsu, Ken Fujimura, Hiroki Umehara, Akihito Nonoyama, Akihito Kiguchiya
  • Publication number: 20220125776
    Abstract: Provided herein are various regimens for treating acute myeloid leukemia (AML) in subjects (e.g, patients) who have undergone one or more prior anti-AML therapies involving venetoclax, and have shown disease progression after the one or more prior therapies. The treatment regimens disclosed herein involve alvocidib, either as a monotherapy, or in combination with cytarabine or a hypomethylating agent, such as decitabine or azacitidine. The treatment regimens disclosed herein do not involve combination therapy of alvocidib with venetoclax.
    Type: Application
    Filed: March 20, 2020
    Publication date: April 28, 2022
    Inventors: David J. Bearss, Stephen Patrick Anthony, Michael Vincent McCullar, Susan Carol Smith
  • Publication number: 20210401399
    Abstract: The present disclosure relates generally to nanoparticle-based imaging, binding, and/or therapy at a targeted anatomical location within a subject. In particular, certain embodiments relate to intraluminal devices and systems configured to apply nanoparticles to an imaging target and/or treatment target within an anatomical lumen and to communicate imaging and/or treatment data wirelessly to one or more external devices.
    Type: Application
    Filed: June 24, 2021
    Publication date: December 30, 2021
    Inventors: Richard J. Linder, David J. Bearss
  • Publication number: 20210261585
    Abstract: Compounds having the following structure (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein one of R1, R2 or R3 is —P(?O)(OH)2, and the other two of R1, R2 and R3 are each H, are provided. Pharmaceutical compositions comprising the compounds, and methods for use of the compounds for treating diseases associated with overexpression of a cyclin-dependent kinase (CDK) are also provided.
    Type: Application
    Filed: May 7, 2021
    Publication date: August 26, 2021
    Inventors: Adam Siddiqui-Jain, David J. Bearss
  • Publication number: 20210228582
    Abstract: Combination therapies for treatment of cancer are provided. The disclosed methods comprise administration of a cyclin-dependent kinase inhibitor and a DNA methyltransferase inhibitor to a mammal in need thereof.
    Type: Application
    Filed: October 2, 2020
    Publication date: July 29, 2021
    Applicant: Sumitomo Dainippon Pharma Oncology, Inc.
    Inventors: David J. Bearss, Steven L. Warner, Adam Siddiqui-Jain, Clifford J. Whatcott, Wontak Kim
  • Publication number: 20210205304
    Abstract: Tartrate salts of the compound of structure (I), (I), crystalline forms thereof, and therapeutic applications thereof for treating solid tumors (e.g., advanced solid tumor) or hematopoietic cancers. Also provided herein are methods for synthesizing the tartrate salts and the crystalline forms thereof.
    Type: Application
    Filed: November 9, 2020
    Publication date: July 8, 2021
    Applicant: Sumitomo Dainippon Pharma Oncology, Inc.
    Inventors: Adam Siddiqui-Jain, Steven L. Warner, Paul Flynn, David J. Bearss, Jason Marc Foulks, Nozomi Tomimatsu, Ken Fujimura, Hiroki Umehara, Akihito Nonoyama, Akihito Kiguchiya
  • Patent number: 11040038
    Abstract: Methods for treating a disease in a subject in need thereof by administering an ACVR1 inhibitor having the following formula (I) are disclosed: including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, and R4 are as defined herein. Subjects that may benefit from treatment may have mutations in their ACVR1 gene. Various diseases may be treated using the described methods, including cancers (e.g., diffuse intrinsic pontine glioma (DIPG)) and genetic disorders (e.g., fibrodysplasia ossificans progressiva (FOP)).
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: June 22, 2021
    Assignee: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
    Inventors: Steven L. Warner, David J. Bearss, Adam Siddiqui-Jain, Clifford J. Whatcott, Jason Marc Foulks, Stephen Patrick Anthony, Paul Flynn, Yuji Fujiwara, Yuka Arikawa
  • Publication number: 20210145830
    Abstract: This document provides methods for determining biological age of mammalian subjects or assessing whether the subjects are aging normally. Also provided herein are methods for determining whether therapeutic treatment or other interventions for reversing or slowing down aging are effective. This document also provides methods and materials for slowing the progression of biological aging.
    Type: Application
    Filed: April 5, 2019
    Publication date: May 20, 2021
    Inventors: Saad J. Kenderian, Neil E. Kay, Reona Sakemura, Steven L. Warner, David J. Bearss, Jason Marc Foulks, Lars Mouritsen, Clifford J. Whatcott
  • Publication number: 20210070715
    Abstract: Compounds having activity as inhibitors of ALK2 kinase and/or JAK2 kinase are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, X, z and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: July 15, 2020
    Publication date: March 11, 2021
    Inventors: Alexis Mollard, Steven L. Warner, Gary A. Flynn, Hariprasad Vankayalapati, David J. Bearss
  • Publication number: 20210052568
    Abstract: The present disclosure provides diagnostic methods useful for predicting a patient's response to alvocidib and guiding a physician decision to administer alvocidib to the patient.
    Type: Application
    Filed: March 10, 2020
    Publication date: February 25, 2021
    Applicant: Sumitomo Dainippon Pharma Oncology, Inc.
    Inventors: Steven L. WARNER, David J. Bearss
  • Publication number: 20210000825
    Abstract: Provided herein is a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein values for the variables (e.g., X1, X2, R2, R3, R4, R5, R6, R7, R8, m, n) are as described herein. Compounds of Formula I, pharmaceutically acceptable salts thereof, pharmaceutical compositions of either of the foregoing, and combinations of any of the foregoing can be used to treat tyrosine kinase non-receptor 1 (TNK1)-mediated diseases, disorders and conditions.
    Type: Application
    Filed: July 2, 2020
    Publication date: January 7, 2021
    Inventors: Adam Siddiqui-Jain, Jeyaprakashnarayanan Seenisamy, Steven L. Warner, Clifford J. Whatcott, David J. Bearss
  • Patent number: 10835537
    Abstract: Combination therapies for treatment of cancer are provided. The disclosed methods comprise administration of a cyclin-dependent kinase inhibitor and a DNA methyltransferase inhibitor to a mammal in need thereof.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: November 17, 2020
    Assignee: Sumitomo Dainippon Pharma Oncology, Inc.
    Inventors: David J. Bearss, Steven L. Warner, Adam Siddiqui-Jain, Clifford J. Whatcott, Wontak Kim
  • Publication number: 20200323851
    Abstract: Described herein are methods for treating ALK5-mediated disease including myelodysplastic syndrome (MDS), anemia and anemia of chronic disease. Also provided are methods of inhibiting ALK5.
    Type: Application
    Filed: January 10, 2020
    Publication date: October 15, 2020
    Inventors: David J. BEARSS, Steven L. WARNER
  • Publication number: 20200316084
    Abstract: Methods for targeting super enhancers by administration of two or more therapeutic agents are provided. The methods are useful for treatment of various super-enhancer-mediated diseases and conditions, such as cancer. Compositions comprising the two or more therapeutic agents are also provided.
    Type: Application
    Filed: December 30, 2019
    Publication date: October 8, 2020
    Inventors: Steven L. WARNER, David J. BEARSS
  • Publication number: 20200297698
    Abstract: A compound of Structure (I): or a pharmaceutically acceptable salt thereof, alone or in combination with a second therapeutic agent, as well as methods of treating a PKM2-mediated disease or disorder using the same are provided herein.
    Type: Application
    Filed: March 20, 2020
    Publication date: September 24, 2020
    Inventors: Steven L. WARNER, David J. BEARSS, Jason Marc FOULKS